Texas Failed to Secure Proposals for Ibogaine Trials
State efforts to launch ibogaine research for substance use hit a standstill after receiving no qualifying bids.
Updated on Oct. 9, 2026 in Substance Abuse
Live Poll
Should the federal government provide funding to states for psychedelic drug research?
On March 31, 2026, Texas officials confirmed that no drug companies submitted proposals for state-funded ibogaine trials. This stalled the planned $50 million investment, which required matching funds from private partners.
Why it matters
The outcome leaves the future of state-led psychedelic treatment research in limbo, as the funding requirement remains a barrier for prospective clinical participants. This development highlights the complex logistics of implementing state-level substance use pilot programs.
The Texas Health and Human Services Commission reported a total of zero qualifying proposals for its planned $50 million ibogaine research initiative. The viability of proceeding with independent state-led programs following this procurement failure remains under investigation.
The players
Texas Health and Human Services Commission
The state agency responsible for managing public health services and the administration of clinical research funding in Texas.
President Donald Trump
The current President of the United States who authorized a federal initiative to support psychedelic research.
The details
The state attempted to initiate clinical research by opening a competitive request for proposals, but the process stalled when no entities met the established criteria. The program was originally designed to pair state funds with private investment to study the effects of ibogaine on substance use disorders. Because Texas law required specific matching investment levels, the absence of industry interest prevented the activation of the allocated budget.
Timeline
March 30, 2026: The Texas Health and Human Services Commission announced no qualifying proposals were received.
March 31, 2026: Texas officials confirmed the failure to secure research proposals.
April 18, 2026: President Donald Trump signed an executive order directing federal funding toward psychedelic research.
Health Landscape
This state-level procurement failure marks a departure from the momentum established by the federal government's recent executive order supporting psychedelic research. It illustrates the disconnect between broad policy initiatives and the practical execution of specific research trials.
While the state trials are on hold, those interested in experimental treatments for substance use should continue to consult with their physicians about FDA-approved care options. It is worth discussing with your doctor what types of research studies or clinical trials may be available to you.
The takeaway
The stalled Texas initiative highlights that even with secured state funding, clinical research progress requires industry participation. Residents should continue to follow official guidance from the Texas Health and Human Services Commission for updates on independent research programs.
Further reading
For more on the current approach to Substance Abuse, explore our library of clinical research and recovery resources.
Source note: This article includes information reported by Columbia Gorge News.
Live Poll
Should the federal government provide funding to states for psychedelic drug research?
